血管生成过程在正常卵巢的发育和生理功能方面已有充分的描述，也在卵巢癌（OC）的启动、进展和转移中发挥着潜在作用。在OC的晚期阶段，癌细胞会向卵巢外部蔓延至盆腔、腹部、肺部或多个其他次要部位，这会严重限制治疗选择的功效，进而导致致命的临床结果。值得注意的是，肿瘤细胞产生了多种血管生成效应因子，从而启动血管生成过程，促进新血管的发展，为肿瘤的生存、扩散和静止微转移提供了必不可少的资源。多种促血管生成效应因子及其信号通路已被发现并进行了功能性特征化，具有潜在的OC临床应用价值。在本综述中，我们提供了当前关于经典和新兴促血管生成效应因子、它们的信号通路和免疫微环境对OC发病的贡献的最新更新。此外，我们全面回顾和讨论了预临床策略、药物再利用和针对血管生成过程的临床试验的重要性，这些策略具有很好的前景，可以更好地管理OC患者。版权所有 © 2023 Elsevier B.V.发表

The process of angiogenesis is well described for its potential role in the development of normal ovaries, and physiological functions as well as in the initiation, progression, and metastasis of ovarian cancer (OC). In advanced stages of OC, cancer cells spread outside the ovary to the pelvic, abdomen, lung, or multiple secondary sites. This seriously limits the efficacy of therapeutic options contributing to fatal clinical outcomes. Notably, a variety of angiogenic effectors are produced by the tumor cells to initiate angiogenic processes leading to the development of new blood vessels, which provide essential resources for tumor survival, dissemination, and dormant micro-metastasis of tumor cells. Multiple proangiogenic effectors and their signaling axis have been discovered and functionally characterized for potential clinical utility in OC. In this review, we have provided the current updates on classical and emerging proangiogenic effectors, their signaling axis, and the immune microenvironment contributing to the pathogenesis of OC. Moreover, we have comprehensively reviewed and discussed the significance of the preclinical strategies, drug repurposing, and clinical trials targeting the angiogenic processes that hold promising perspectives for the better management of patients with OC.Copyright © 2023. Published by Elsevier B.V.